The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody
Open accessAbstract
BACKGROUND: Alloantigen-activated T cells express the high-affinity interleukin-2 receptor. Specific blockade of this receptor with the human IgG1 monoclonal antibody daclizumab may prevent rejection of allografts after cardiac transplantation without inducing global immunosuppression. METHODS: We randomly assigned 55 nonsensitized patients undergoing a first cardiac transplantation to receive either induction therapy with daclizumab (1.0 mg per kilogram of body weight), given intravenously within 24 hours after cardiac-transplantation surgery and every two weeks thereafter, for a total of five doses, or generalized immunosuppressive therapy. Concomitant immunosuppression was achieved in both groups with cyclosporine, mycophenolate mofetil, and prednisone. The primary end points were the incidence and severity of acute rejection, and the length of time to a first episode of biopsy-confirmed rejection. RESULTS: Of the 55 patients in the study, 28 were randomly assigned to receive daclizumab and 27 served as the control group. During induction therapy, the mean frequency of acute rejection episodes (defined as a histologic grade of 2 or higher according to the classification of the International Society of Heart and Lung Transplants) was 0.64 per patient in the control group and 0.19 per patient in the daclizumab group (P=0.02). Acute rejection developed in 17 of 27 patients in the control group (63 percent), as compared with 5 of 28 patients in the daclizumab group (18 percent; relative risk, 2.8; 95 percent confidence interval, 1.1 to 7.4; P=0.04). Throughout follow-up, there were nine patients with episodes of acute rejection of histologic grade 3 in the control group, as compared with two in the daclizumab group (P= 0.03), and the time to a first episode of rejection was significantly longer in the daclizumab group (P=0.04). There were no adverse reactions to daclizumab and no significant differences between the groups in the incidence of infection or cancer during follow-up. CONCLUSIONS: Induction therapy with daclizumab safely reduces the frequency and severity of cardiac-allograft rejection during the induction period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
SOLLINGER, H. W. (1995) · Transplantation · doi:10.1097/00007890-199508000-00003 · Cited by 1,363
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
The IL-2/IL-2 receptor system: A current overview
Taniguchi, T. (1993) · Cell · doi:10.1016/0092-8674(93)90152-g · Cited by 761
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Self-citationUretsky, B. F., Murali, S., Reddy, P. S., Rabin, B., Lee, A., Griffith, B. P., Hardesty, R. L., Trento, A., & Bahnson, H. T. (1987) · Circulation · doi:10.1161/01.cir.76.4.827 · Cited by 531
Vanderlugt, C. J., & Miller, S. D. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80012-4 · Cited by 331
Indirect recognition of donor HLA-DR peptides in organ allograft rejection.
Liu, Z., Colovai, A. I., Tugulea, S., Reed, E. F., Fisher, P. E., Mancini, D., Rose, E. A., Cortesini, R., Michler, R. E., & Suciu-Foca, N. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118898 · Cited by 244
Self-citationMultiple levels of peripheral tolerance
Arnold, B., Schönrich, G., & Hämmerling, G. J. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90317-e · Cited by 213
Do B cells drive the diversification of immune responses?
Mamula, M. J., & Janeway, C. A. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90274-o · Cited by 185
Cited by
Costanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Structural Biology of Shared Cytokine Receptors
Wang, X., Lupardus, P., LaPorte, S. L., & Garcia, K. C. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090616 · Cited by 408
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
“Both monoclonal antibodies resulted in superior allograft survival compared with controls, however, HAT was less immunogenic and resulted in a better survival compared with the murine antibody. Recently, 55 patients undergoing first cardiac allograft were randomised to cyclosporine, mycophenolate mofetil and prednison…”
Background
Metadata
- Authors
- Beniaminovitz, A., Itescu, S., Lietz, K., Donovan, M., Burke, E. M., Groff, B. D., Edwards, N., & Mancini, D. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-03-02
- Volume
- 342
- Issue
- 9
- Pages
- 613-619
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2341139192
- Cited by
- 261
- References
- 22
- FWCI
- 26.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody. https://app.cochat.ai/papers/10.1056/nejm200003023420902
- The paper
- Beniaminovitz, A., Itescu, S., Lietz, K., Donovan, M., Burke, E. M., Groff, B. D., Edwards, N., & Mancini, D. M. (2000). Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody. New England Journal of Medicine. https://doi.org/10.1056/nejm200003023420902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.